IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product
development, today announced that an ongoing clinical trial using the Company's
bioFILM PA(TM) test shows that in 71% of cases, the test suggests different
antibiotic treatment choices (p less than 0.0001) for Cystic Fibrosis (CF)
patients with Pseudomonas aeruginosa (PA) chronic lung infections compared to
conventional testing.


Drs. Valerie Waters and Yvonne Yau of The Hospital for Sick Children in Toronto
will be presenting the results in a poster at The 24th Annual North American
Cystic Fibrosis Conference in Baltimore, October 21st to October 23rd. The
poster provides an update on the randomized double blind controlled clinical
trial currently underway, the purpose of which is to determine if the use of the
bioFILM PA(TM) test leads to improved CF patient outcomes. 


"To date, physicians have based much of their treatment for Cystic Fibrosis lung
infections on a combination of conventional susceptibility testing and educated
guesses," said Ken Boutilier, President and CEO of Innovotech Inc. "It is our
understanding from speaking with physicians that there are many occasions when
conventional testing indicates that the bacteria is resistant to all available
antibiotics. The bioFILM PA(TM) test has provided results which question the
validity of current methods and may ultimately lead to differences in patient
outcomes." 


Innovotech's team will be in attendance at the conference. Please visit booth
718 for more information regarding bioFILM PA(TM) or contact Innovotech
directly.


bioFILM PA(TM) is the world's first biofilm susceptibility test, designed to
assist physicians in the selection of the most effective combination antibiotic
treatment of patients with PA infections, such as those that occur in patients
with CF. Biofilms are known to be present in CF lung infections, and are up to
1000 times more difficult to treat than non-biofilm infections. According to the
National Institute of Health, 80% of all human infections are biofilm-related.
PA infections are also common in patients with hospital-acquired infections such
as ventilator-associated pneumonia and those found in patients with burns and
wounds.


Cystic Fibrosis is a genetic disease affecting predominantly children and young
adults and is one of the most recognized biofilm diseases. CF patients are prone
to frequent lung infections that are often fatal.


About The 24th Annual North American Cystic Fibrosis Conference 

The North American Cystic Fibrosis Conference is the largest gathering of cystic
fibrosis (CF) professionals in the world, providing superior continuing medical
education and a multi-disciplinary approach to the advancement of CF research,
treatments and care. For more information visit
https://www.nacfconference.org/Default2010.asp.


About Innovotech Inc.: 

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are responsible
for a host of diseases both in human health and agriculture due to their
inherent resistance to existing antibiotics and disinfectants. There are
currently no antibiotics, disinfectants, diagnostics or regulatory standards
designed specifically for biofilm-forming organisms. 


Innovotech currently has two products in advanced stages of development: bioFILM
PA(TM), the first diagnostic test to assist physicians in the selection of the
most effective combination antibiotic treatment of patients with biofilm-based
chronic lung infections and Agress(TM) a unique, environmentally friendly seed
treatment and plant spray designed to protect crops against both bacterial and
fungal infections.


This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024